Novavax, Inc.
NVAX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $1,408 | $1,021 | $1,032 | $1,288 |
| - Cash | $268 | $264 | $263 | $530 |
| + Debt | $251 | $228 | $229 | $230 |
| Enterprise Value | $1,391 | $985 | $998 | $989 |
| Revenue | $70 | $239 | $667 | $88 |
| % Growth | -70.6% | -64.1% | 654.9% | – |
| Gross Profit | $49 | $225 | $653 | $52 |
| % Margin | 69.5% | 94.1% | 97.9% | 58.5% |
| EBITDA | -$191 | $121 | $534 | -$53 |
| % Margin | -271.1% | 50.4% | 80.1% | -60.6% |
| Net Income | -$202 | $107 | $519 | -$81 |
| % Margin | -287.3% | 44.5% | 77.8% | -91.8% |
| EPS Diluted | -1.25 | 0.6 | 2.93 | -0.51 |
| % Growth | -308.3% | -79.5% | 674.5% | – |
| Operating Cash Flow | $108 | -$127 | -$186 | -$173 |
| Capital Expenditures | -$2 | -$0 | -$2 | -$2 |
| Free Cash Flow | $106 | -$128 | -$187 | -$175 |